Per Johanson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2299675/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Longâ€Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. Journal of the American Heart Association, 2021, 10, e017008.	3.7	17
2	Longâ€Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUSâ€TIMI 54 Trial. Journal of the American Heart Association, 2021, 10, e020446.	3.7	7
3	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care, 2021, 44, 2573-2581.	8.6	13
4	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European Heart Journal, 2020, 41, 1625-1632.	2.2	27
5	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 142, 1623-1632.	1.6	51
6	Gut Microbiotaâ€Dependent Trimethylamine Nâ€oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUSâ€TIMI 54 Trial. Journal of the American Heart Association, 2020, 9, e015331.	3.7	32
7	Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUSâ€IIMI 54 Trial. Journal of the American Heart Association, 2020, 9, e015785.	3.7	7
8	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.	7.4	340
9	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 1569-1577.	1.6	94
10	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 200-206.	3.0	25
11	Development Strategy and Relative Bioavailability of a Pediatric Tablet Formulation of Ticagrelor. Clinical Drug Investigation, 2019, 39, 765-773.	2.2	3
12	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2528-2536.	1.6	415
13	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54. Journal of the American Heart Association, 2018, 7, e009260.	3.7	8
14	Efficacy and Safety of Ticagrelor OverÂTime in Patients With Prior MI inÂPEGASUS-TIMI 54. Journal of the American College of Cardiology, 2017, 70, 1368-1375.	2.8	74
15	Decreased admissions and hospital costs with a neutral effect on mortality following lowering of the troponin T cutoff point to the 99th percentile. Cardiology Journal, 2017, 24, 612-622.	1.2	9
16	All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart, 2016, 102, 926-933.	2.9	70
17	Invasive strategies and outcomes for non-ST-segment elevation acute coronary syndromes: a twelve-year experience from SWEDEHEART. EuroIntervention, 2016, 12, 1108-1116.	3.2	17
18	Patients admitted to hospital with chest pain — Changes in a 20-year perspective. International Journal of Cardiology, 2013, 166, 141-146.	1.7	10

Per Johanson

#	Article	IF	CITATIONS
19	Prehospital ECG signs of acute coronary occlusion are associated with reduced one-year mortality. International Journal of Cardiology, 2013, 168, 3594-3598.	1.7	9
20	Small Changes in Troponin T Levels Are Common in Patients With Non–ST-Segment Elevation Myocardial Infarction and Are Linked to Higher Mortality. Journal of the American College of Cardiology, 2013, 62, 1231-1238.	2.8	88
21	Third Universal Definition of Myocardial Infarction. Circulation, 2012, 126, 2020-2035.	1.6	2,722
22	Troponin T Percentiles from a Random Population Sample, Emergency Room Patients and Patients with Myocardial Infarction. Clinical Chemistry, 2012, 58, 628-637.	3.2	134
23	Third universal definition of myocardial infarction. European Heart Journal, 2012, 33, 2551-2567.	2.2	2,447
24	Inequalities in the early treatment of women and men with acute chest pain?. American Journal of Emergency Medicine, 2012, 30, 1515-1521.	1.6	16
25	Characteristics of and outcome for patients with chest pain in relation to transport by the emergency medical services in a 20-year perspective. American Journal of Emergency Medicine, 2012, 30, 1788-1795.	1.6	29
26	Association Between Adoption of Evidence-Based Treatment and Survival for Patients With ST-Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2011, 305, 1677.	7.4	356
27	Influence of ST-Segment Recovery on Infarct Size and Ejection Fraction in Patients With ST-Segment Elevation Myocardial Infarction Receiving Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2010, 105, 1223-1228.	1.6	14
28	Optimal Time-Point of ST-Segment Assessment for Risk-Stratification Following Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2010, 105, 1648-1649.	1.6	0
29	Effects of ischemic preconditioning and arterial collateral flow on ST-segment elevation and QRS complex prolongation in a canine model of acute coronary occlusion. Journal of Electrocardiology, 2009, 42, 19-26.	0.9	34
30	ST Resolution 1 Hour After Fibrinolysis for Prediction of Myocardial Infarct Size: Insights from ASSENT 3. American Journal of Cardiology, 2009, 103, 154-158.	1.6	5
31	The value of both ST-segment and QRS complex changes during acute coronary occlusion for prediction of reperfusion-induced myocardial salvage in a canine model. Journal of Electrocardiology, 2007, 40, 18-25.	0.9	33
32	Electrocardiogram dynamics for risk stratification in ST-segment elevation myocardial infarction—immediate and serially updated information on outcome. Journal of Electrocardiology, 2006, 39, S75-S78.	0.9	1
33	Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). American Journal of Cardiology, 2005, 95, 611-614.	1.6	25
34	An Academic ECG Core Lab Perspective of the FDA Initiative for Digital ECG Capture and Data Management in Large-Scale Clinical Trials. Drug Information Journal, 2005, 39, 345-351.	0.5	1
35	A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy. European Heart Journal, 2005, 26, 1726-1733.	2.2	11
36	Admission Troponin T and measurement of ST-segment resolution at 60 min improve early risk stratification in ST-elevation myocardial infarction. European Heart Journal, 2004, 25, 113-120.	2.2	23

Per Johanson

#	Article	IF	CITATIONS
37	Clinical Utility of Serial and Continuous ST-Segment Recovery Assessment in Patients With Acute ST-Elevation Myocardial Infarction. Circulation, 2004, 110, e533-9.	1.6	19
38	Assessment of derived 12-lead electrocardiograms using general and patient-specific reconstruction strategies at rest and during transient myocardial ischemia. American Journal of Cardiology, 2004, 94, 1529-1533.	1.6	15
39	ST-segment analyses and residual thrombi in the infarct-related artery: a report from the ASSENT PLUS ST-monitoring substudy. American Heart Journal, 2004, 147, 853-858.	2.7	8
40	ST-segment monitoring in patients with acute coronary syndromes. Current Cardiology Reports, 2003, 5, 278-283.	2.9	9
41	The supplementary effect of QRS changes on the inverse relationship between ST changes and salvage. Journal of Electrocardiology, 2003, 36, 13-16.	0.9	2
42	"Mirror-lake―serial relationship of electrocardiographic and biochemical indices for the detection of reperfusion and the prediction of salvage in patients with acute myocardial infarction. American Heart Journal, 2003, 146, 757-763.	2.7	10
43	Early repolarization: friend or foe?. American Journal of Medicine, 2003, 115, 237-240.	1.5	2
44	Prognostic value of ST-segment resolution—when and what to measure. European Heart Journal, 2003, 24, 337-345.	2.2	44
45	The first ISCE board of [ldquo]Trustees[rdquo] overview panel session: Ischemia monitoring, state of the art. Journal of Electrocardiology, 2002, 35, 207.	0.9	1
46	Continuous ST monitoring: A bedside instrument? A report from the Assessment of the Safety of a New Thrombolytic (ASSENT 2) ST Monitoring Substudy. American Heart Journal, 2001, 142, 58-62.	2.7	14
47	Clinical implications of early ST-segment variability. A report from the ASSENT 2 ST-monitoring sub-study. Coronary Artery Disease, 2001, 12, 277-283.	0.7	17
48	ST Variability during the First 4 Hours of Acute Myocardial Infarction Predicts 1-Year Mortality. Annals of Noninvasive Electrocardiology, 2001, 6, 198-202.	1.1	11